Once Daily 3TC, Efavirenz and ddI for HIV Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00214435|
Recruitment Status : Unknown
Verified September 2005 by 407 Doctors.
Recruitment status was: Recruiting
First Posted : September 22, 2005
Last Update Posted : October 25, 2005
|Condition or disease||Intervention/treatment||Phase|
|HIV Infection AIDS||Drug: once daily minimum 3-drug regimen of anti-retroviral medications||Phase 4|
Rationale: ‘TEddI’ will enable a once-daily treatment strategy to be studied and provide information on effectiveness, patient adherence and quality of life and the tolerability of such regimens.
Hypothesis: The study hypothesis is that an antiretroviral regimen comprising of three agents taken once daily will have higher levels of adherence than a regimen requiring more frequent dosing.
Primary objective: To determine over 24 weeks the levels of adherence in two groups of HIV-infected subjects randomised to receive either a once daily minimum 3-drug regimen or to continue a minimum 3-drug regimen requiring more frequent dosing.
Secondary objectives: The secondary objectives of the study will include:
- To estimate the proportion of patients with treatment failure where treatment failure is defined as:
- HIV-1 RNA viral load of >400 copies/ml on two consecutive occasions more than one month apart, OR
- Discontinuation of treatment for any reason (where subsequent therapy does not comply with the study regimen change guidelines outlined in section 3.3.3)
- Proportion of patients with plasma HIV-RNA less than 50 copies/ml (using an ultrasensitive assay) at 24 and 48 weeks
- Change from baseline in CD4 cell count at 24 and 48 weeks
- Changes from baseline in subjects’ quality of life at 24 and 48 weeks
- Changes from baseline based on DASS 21 scores at 24 and 48 weeks
- Incidence and severity of adverse events and abnormal laboratory values (grade 3 & 4) at 24 and 48 weeks
- Proportion of patients remaining on assigned treatment Study Design This is a randomised, open-label, multi-centre, prospective, 48-week study comparing a 3 (or more) drug once-daily antiretroviral regimen with any 3 (or more) drug regimen in which at least 1 drug must be taken at least twice daily.
One hundred and twenty (120) subjects will be recruited and randomised in a 1:1 ratio to one of two open-label treatment regimens and will continue to receive randomised treatment until week 24:
Arm 1: (Once daily arm) commence treatment with a once-a-day combination of licensed antiviral medications (such as EFV/ddI/3TC, EFV/3TC/TDF or ATV/3TC/TDF).
Arm 2: (Continuation arm) continue current ART (minimum 3-drugs) dosed twice daily or more frequently
Following week 24, patients will have the option to continue randomised treatment for a further 24 weeks or switch to the once daily treatment arm. In all cases, patients will be followed up for 48 weeks from the baseline visit.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily|
|Study Start Date :||May 2004|
- - levels of adherence
- - proportion of patients with treatment failure where treatment failure is defined
- - HIV-1 RNA viral load of >400 copies/ml on two consecutive occasions more than one month apart, OR discontinuation of treatment for any reason (where subsequent therapy does not comply with the study regimen change guidelines outlined in section 3.3.3)
- - proportion of patients with plasma HIV-RNA less than 50 copies/ml (using an ultrasensitive assay) at 24 and 48 weeks
- - change from baseline in CD4 cell count at 24 and 48 weeks
- - changes from baseline in subjects’ quality of life at 24 and 48 weeks
- - changes from baseline based on DASS 21 scores at 24 and 48 weeks
- - incidence and severity of adverse events and abnormal
- - laboratory values (grade 3 & 4) at 24 and 48 weeks
- - proportion of patients remaining on assigned treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214435
|Contact: David A Baker, MB ChB||02 9332 email@example.com|
|Contact: Robyn Vale, RN||02 9332 2531|
|Australia, New South Wales|
|Sydney, New South Wales, Australia, 2010|
|Contact: David A Baker, MB ChB 02 9332 2531 firstname.lastname@example.org|
|Principal Investigator: David A Baker, MB ChB|
|Principal Investigator:||David A Baker, MB ChB||407 Doctors|